MN-DIGI-INTL
15.6.2021 15:02:07 CEST | Business Wire | Press release
Digi International (NASDAQ: DGII) (www.digi.com ), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced the expansion of its market-leading ConnectCore® family of products with the introduction of the Digi ConnectCore® 8M Mini System on Module (SOM).
Digi ConnectCore 8M Mini is a highly integrated and cost-effective SOM platform based on the NXP® i.MX 8M Mini applications processor. Featuring the optimal balance of performance, power and cost, it’s designed for mission-critical industrial, medical, transportation and agriculture applications. Digi ConnectCore simplifies embedded product development thanks to integrated memory, power management, pre-certified wireless, advanced security and the complete, open-source Digi Embedded Yocto Linux software platform based on Yocto Project™ or Android-based Digi Embedded Android, setting the product apart and enabling manufacturers to get to market faster with lower risk and cost and to focus on their core competency.
“Digi is excited to be expanding the Digi ConnectCore® family of products," said Steve Ericson, General Manager, OEM Solutions at Digi International. "We remain dedicated to delivering advanced solutions that simplify product development for manufacturers seeking secure, connected products that also help reduce the cost of R&D. The Digi ConnectCore 8M Mini SOM extends that commitment and delivers increased capability while lowering the total cost of ownership.”
With versatile, power-efficient ARM® Cortex® -A53 and Cortex-M4 processing cores, rich multimedia (2D/3D GPU, VPU, MIPI-DSI/CSI, SAI, PDM) and advanced connectivity (802.11 ac, Bluetooth 5, Gigabit Ethernet), the Digi ConnectCore 8M Mini is ideal for Internet of Things (IoT), human-machine interface (HMI), equipment monitoring, audio/voice, edge computing and machine learning applications.
Security and longevity are at the heart of the Digi ConnectCore 8M Mini’s design. Digi TrustFence® delivers a tested and fully integrated device security framework designed for the long product life cycle of embedded devices. Additionally, the i.MX 8M Mini processor is industrial qualified and backed by NXP’s Product Longevity Program, ensuring long-term availability of 10-plus years.
The Digi ConnectCore 8M Mini’s feature set makes it the only SOM among its competitors to offer Bluetooth 5 compatibility and cellular enablement, as well as Digi’s proprietary TrustFence security framework. At 40 x 45 x 3.5 mm, its physical hardware size is also among the smallest in the industry. Access a full list of additional Digi 8M Mini features here .
Availability
Initial Digi ConnectCore 8M Mini development kits and software will be available through global distribution partners June 15, 2021.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. We help our customers create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, we’ve helped our customers connect over 100 million things and growing. For more information, visit Digi's website at www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005035/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom